ABVX · Abivax SA

The thesis

Abivax's shares are modestly more likely to beat the S&P 500 over the next three months, because the company guides its US marketing application (new drug application, NDA) for obefazimod in ulcerative colitis to the fourth quarter of 2026. A submission announced by 31 December 2026 would confirm the timetable; guidance moving into 2027 or an FDA request for more safety work would break the case.

The American depositary shares (ADSs) closed at $90.20 on 12 November 2026. That is 39.4% below the 52-week intraday high of $148.83 set on 24 December 2025, and the three-month change is −24.2%. The shares closed at $84.17 on 5 November 2026 and recovered to $91.44 by 11 November 2026.

Company news on 3 November 2026 announced participation in fall investor conferences and gave no change to the filing timetable. Abivax's 6-K filing with the US Securities and Exchange Commission (SEC) dated 29 June 2026 lists "Fourth Quarter 2026 – Planned NDA submission for obefazimod in UC" and says the company is on track after a positive pre-NDA interaction with the US Food and Drug Administration (FDA). The 21 September 2026 half-year results repeated that guidance.

Bullish and bearish views on Abivax SA

The bull case on Abivax SA (ABVX), in brief: the filing timetable is intact. The bear case: analysts have trimmed targets.

Bull case

• The filing timetable is intact. The 29 June 2026 filing and the 21 September 2026 half-year results both put the NDA submission in the fourth quarter of 2026. FDA feedback in the pre-NDA interaction covered content, format and strategy.
• Maintenance efficacy is documented. The company's 1 June 2026 release reported Week-44 clinical remission of 50.8% at 25 mg and 51.3% at 50 mg, against 10.4% on placebo.
• Funding runs past launch. Cash and short-term investments were €402.4 million at 30 June 2026, and net proceeds from the July offering were €767.1 million. The half-year release guides the cash runway into the fourth quarter of 2029.
• Some analysts keep high targets. Guggenheim reiterated Buy with a $175 target on 20 October 2026, per Benzinga.
• Takeover interest has been reported. La Lettre reported on 17 July 2026, as relayed by Benzinga, that Abivax re-engaged the investment bank Centerview for talks with large drugmakers. The company has not confirmed any approach.

Bear case

• Analysts have trimmed targets. Wedbush lowered its target to $96 with a Neutral rating, reported by Benzinga on 21 October 2026, after cutting from $140 to $118 on 22 September 2026.
• The price sits below the offering. The July offering priced 6.40 million ADSs at $125.00 each (Benzinga, 1 July 2026), well above the $90.20 close of 12 November 2026.
• Losses are widening. The first-half 2026 net loss was €165.9 million, against €100.8 million a year earlier, per the half-year results.
• One asset carries the company. The company has reported malignancy cases in the 50 mg group. A safety question or an FDA request for more data would hit the whole valuation; none has been disclosed.
• Shares trail both moving averages. The close of $90.20 on 12 November 2026 is under the 50-day average of $95.37 and the 200-day average of $112.70.

Price setup

The market has priced in a lower value than the July offering did: the shares closed at $118.96 on 14 August 2026, three months before the latest close of $90.20, and the $125.00 offering price from 1 July 2026 sits above both.

The closes since 5 November 2026 were $84.17, $85.73 (6 November 2026), $87.00 (9 November 2026), $90.00 (10 November 2026), $91.44 (11 November 2026) and $90.20 (12 November 2026). The 52-week closing low is $72.50, set on 2 June 2026. The early-November closes are the nearest recent floor. The 50-day average of $95.37 is the nearest overhead level, and the 200-day average is $112.70, both as of 12 November 2026.

As a foreign private issuer, Abivax files no Form 4 insider-transaction reports, so insider activity cannot be read from US filings. The company's only 2026 annual report on EDGAR is the 20-F filed 23 March 2026 for the year ended 31 December 2025.

Catalysts ahead

• ~10 December 2026 (est.): Monthly French capital and voting-rights disclosure. Shows any change in the ADS-related share count after the July offering.
• ~31 December 2026 (est.): US NDA submission for obefazimod in ulcerative colitis, guided to the fourth quarter of 2026. An on-time submission keeps the regulatory clock intact; a slip into 2027 would break the timetable.

What would change the view

A daily close below $85, which would return the shares to the early-November low area, where they closed at $84.17 on 5 November 2026. Guidance moving the NDA submission into 2027, or an FDA request for added safety work, would also break the case.

The risks this note tracks, each with what would confirm it:

• The NDA submission slips beyond the fourth-quarter 2026 guidance. Confirmed by: company guidance moves submission into 2027, or no submission is announced by 31 December 2026.
• The malignancy cases in the 50 mg group lead regulators to ask for added safety work. Confirmed by: Abivax discloses an FDA request for additional safety data.
• Analysts keep cutting targets despite reaffirmed guidance. Confirmed by: more target cuts or downgrades following Wedbush's cut to $96 on 21 October 2026.

What it trades with

Abivax trades on its own regulatory path. The valuation moves with obefazimod news more than with the wider biotech index, and the shares are listed in both Paris and New York. The Euronext Paris session trades before the US open and often sets the ADS opening price. The takeover report in La Lettre on 17 July 2026 adds an event risk that does not follow sector moves.